MedTrace Logo

Project Survival-Prospective Biomarker Discovery

NCT02781012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 436

Last updated 2019-04-16

No results posted yet for this study

Summary

This sample-collection study is open to participants in several categories: healthy volunteers (with or without a family history of pancreatic cancer) and individuals diagnosed with pancreatitis or any stage of pancreatic cancer. All participants will submit urine, saliva and blood samples; pancreatitis and pancreatic cancer patients will also submit tissue samples if biopsy/ies or surgery is part of the care being provided by their doctor. In partnership with Berg Health, LLC, biomarkers will be investigated for potential use in early detection of pancreatic cancer, to determine prognosis of patients, and to find the most appropriate treatments for patients.

Conditions

Sponsors & Collaborators

  • BPGbio

    collaborator INDUSTRY

  • Pancreatic Cancer Research Team

    lead OTHER

Principal Investigators

  • A. James Moser, MD · Beth Israel Deaconess Medical Center, Harvard University

  • Tomislav Dragovich, MD · Banner Health - MD Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781012 on ClinicalTrials.gov